← Back to Search

Vitamin Supplement

4000 IU Vitamin D for Osler-Weber-Rendu Syndrome

Phase 2
Waitlist Available
Research Sponsored by St. Paul's Hospital, Canada
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up baseline, 3 months, and 6 months
Awards & highlights

Summary

This trial is testing if taking vitamin D regularly can help reduce the frequency and severity of nosebleeds in patients with HHT. Vitamin D might make blood vessels stronger and less likely to bleed. The study will compare different amounts of vitamin D to see which works best.

Eligible Conditions
  • Osler-Weber-Rendu Syndrome

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~baseline, 3 months, and 6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and baseline, 3 months, and 6 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Change in Epistaxis Severity Score
Secondary outcome measures
Change in Modified Lund-Kennedy Score

Trial Design

3Treatment groups
Experimental Treatment
Placebo Group
Group I: 4000 IU Vitamin DExperimental Treatment1 Intervention
Group II: 1000 IU Vitamin DExperimental Treatment1 Intervention
Group III: PlaceboPlacebo Group1 Intervention
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Vit D
2016
Completed Phase 4
~1210

Find a Location

Who is running the clinical trial?

St. Paul's Hospital, CanadaLead Sponsor
44 Previous Clinical Trials
12,660 Total Patients Enrolled
~8 spots leftby Sep 2025